Author

James L. Gulley

h-index 13 View on Semantic Scholar

We have 3 of 60 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Nov 2026

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients

BACKGROUND TGF-β drives fibroblast activation in cancer and is a resistance biomarker to PD-1/PD-L1 blockade. METHODS Focusing on the tumor stroma, we characterized the impact of neoadjuvant treatment with bintrafusp alfa (BA), a dual PD-L1 and TGF-β inhibitor, in a window-of-opportunity study with 6 patients with head...

Caroline Hoffmann, Jan-Timon Werle, P. Sirven et al. · Journal of Clinical Investig... · 0 citations

Open access Sep 2026

Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance

Abstract Background Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1+CD8+ T cells, cytotoxic CD8+ T cells, and lymphoid aggregates have been associated with CPB responsiven...

C. Minnar, Masaya Miyamoto, Asma S. Khelifa et al. · Journal for ImmunoTherapy of... · 0 citations

Open access Jul 2026

Immunological targeting of the endogenous retroviral protein ERVMER34-1 in carcinomas promotes epitope spread and enhances response to PD-L1 blockade 2306293

The clinical development of a therapeutic cancer vaccine targeting the retroviral envelope protein ERVMER34-1 is supported, which would represent a new class of therapeutic cancer vaccine targeting ERVs.

D. Hamilton, Maria del Mar Maldonado, Renee N. Donahue et al. · Journal of Immunology · 0 citations